# Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Canonical URL: https://biopharmsignal.com/news/PRME/prime-medicine-receives-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-pm359-for-the-treatment-of-chronic-granulomatous-disease-cgd
Ticker: PRME
Company: Prime Medicine
Source: Prime Medicine
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.primemedicine.com
## Summary

-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47 phox -deficient CGD -- -- Designation enables early and intensive FDA engagement, and provides

## Article Body
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47 phox -deficient CGD -- -- Designation enables early and intensive FDA engagement, and provides
## Recent Company News
- 2026-06-25 13:46 EST — [Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)](https://biopharmsignal.com/news/PRME/prime-medicine-receives-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-pm359-for-the-treatment-of-chronic-granulomatous-disease-cgd) — Source: Prime Medicine
- 2026-06-25 13:46 EST — [Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease](https://biopharmsignal.com/news/PRME/prime-medicine-announces-new-zealand-clearance-of-clinical-trial-application-for-pm577a-in-h1069q-mutated-wilson-disease) — Source: Prime Medicine
- 2026-06-25 13:46 EST — [Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/PRME/prime-medicine-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Prime Medicine
- 2026-06-25 13:46 EST — [Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/PRME/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Prime Medicine
- 2026-06-25 13:46 EST — [Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy](https://biopharmsignal.com/news/PRME/prime-medicine-to-host-virtual-kol-event-to-showcase-wilson-s-disease-strategy) — Source: Prime Medicine
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)